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The metabolic equivalent (MET) is a widely used physiological concept for quantifying levels of 
habitual physical activity and cardiorespiratory fitness (CRF) by conveying oxygen consumption 
requirements of physical activities as multiples of resting or basal metabolic rate (RMR). It may also 
be used as a means of prescribing workload for exercise training in patient groups, including those 
attending cardiac rehabilitation (CR). One MET is considered equivalent to the oxygen consumed per 
kg of body mass at rest1  (whilst sitting) and, due to practical issues with direct metabolic cart 
measurement, it is conventionally approximated as 3.5 ml∙kg–1∙min–1. This expression of resting energy 
expenditure has been incorporated within physical activity position statements and guidelines.2,3 
However, a number of factors including age, gender, body mass (fat-free mass), cardio-metabolic 
health, and CRF influence RMR,4  which might limit the broad applicability of the conventional 1 MET 
at a population level. Widely prescribed cardiac medications, namely beta blockers, have also been 
cited to influence RMR with some inconsistent findings in males.5 We aimed to evaluate the potential 
limitations of using the estimated MET in a cohort of patients with coronary heart disease (CHD), in 
which we recently reported a positive association between skeletal muscle mass and peak oxygen 
uptake (V̇O2peak).6 We hypothesised that patients with lower skeletal muscle mass would also have 
lower RMR, determined by resting respiratory gas analysis, and this would impact on the accuracy of 
the aerobic exercise prescription based on METs. 
 
In patients with diagnosed CHD, we measured resting V̇O2 recorded whilst lying for 15 minutes in a 
semi-supine position in a quiet room, following standardised instructions to avoid physical activity and 
limit food intake in the hours prior to testing. Patients’ V̇O2 was continuously recorded using an Oxycon 
Pro metabolic gas cart (Jaeger, Hochberg, Germany). The average V̇O2 over the final 30 seconds of 
data collected was reported as the patient’s RMR (ml∙kg–1∙min–1). Dual X‐ray absorptiometry scans 
were conducted as previously reported.6 Skeletal muscle mass was expressed as appendicular lean 
mass (lean mass in both arms and legs) and reported as skeletal muscle index (SMI; kg m−2). Maximal 
cardiopulmonary exercise testing using the modified Bruce protocol was conducted as previously 
  
reported.6 V̇O2 was recorded over the last 30 seconds of each test stage, and the final 30 seconds of 
the symptom limited or maximal tolerance test (V̇O2peak). The V̇O2 at the end of stage one, and at 
V̇O2peak were divided by 3.5 ml∙kg–1∙min–1 (reference value for resting MET) to establish the estimated 
MET level of the stage 1 and peak exercise workload. The V̇O2 at the end of stage one, and at V̇O2peak 
were also divided by each patient’s RMR, to establish the true MET level of the graded/uphill treadmill 
walk.  
In 70 patients with CHD (mean ± SD; age 63.1 ± 10.0 years; male 86%; body mass 84.7 ± 13.4 kg), 
resting, semi-supine V̇O2 was lower than 3.5 ml∙kg-1∙min-1 (mean resting V̇O2 = 2.8 ±0.5 ml∙kg-1∙min-1; 
Table 1). This mean RMR is consistent with other studies in apparently healthy elderly men,6 and a 
comparable large cohort of overweight male and female patients (mean MET= 2.58 ± 0.4 ml ∙kg-1∙min-
1) with CHD, which indicated that the 3.5 ml∙kg-1∙min-1 significantly overestimated resting oxygen 
consumption by 30-35%.7 In our study, patients with a normal SMI had a higher resting V̇O2 (2.9 ± 0.5 
ml∙kg-1∙min-1), than patients with a low SMI (resting V̇O2 = 2.6 ± 0.3 ml∙kg-1∙min-1).   
When calculating exercise-related MET equivalents, if all patients were assumed to have a RMR of 3.5 
ml∙kg–1∙min–1, there was no difference (P=0.208) in the METs required to perform stage 1 of the Mod 
Bruce protocol between the appendicular skeletal mass groups (low SMI group = 3.3 METs; normal 
SMI group = 3.6 METs). However, when a patient’s RMR was used to calculate the true MET value, 
there was a between-group difference in METs required to perform stage 1 of the Bruce protocol (low 
SMI group = 5.0 METs; normal SMI group = 4.1 METs; P=0.049). Moreover, patients with low SMI also 
had a significantly lower V̇O2peak compared to patients with normal SMI. However, patients with low 
SMI were older, with a total lower body mass (Table 1). 
 
In patients with CHD, RMR was 17-26% lower than the estimated MET value of 3.5 ml∙kg-1∙min-1. These 
findings are similar to those of Savage and co-workers5 who showed that supine RMR was 23-36% 
lower, in overweight, and healthy weight patients with CHD. Our findings have important implications 
for exercise prescription in patients with CHD. If RMR is estimated at 3.5 ml∙kg–1∙min–1, the intensity 
  
of walking over flat ground, at 2.7 km.h-1 (stage 1 of the modified Bruce protocol) is 3.3 METs. 
However, this activity is almost 4x resting RMR in CHD patients with normal SMI, and almost 5x RMR 
in CHD patients with low SMI. Based on these findings we conclude that the relative intensity of 
physical activity is underestimated based on a conventional MET, particularly in those with lower 
appendicular skeletal muscle mass. It may therefore be inappropriate to estimate the intensity of 
exercise using existing reference values in these patients. 
 
Further examples of how RMR can influence individual exercise prescription are as follows; If a patient 
has an RMR of 3.5 ml∙kg-1∙min-1, an exercise performed at an workload requiring a V̇O2 of 18 ml∙kg–
1∙min–1 would be five times their RMR (5.1 METs).2 However, an individual with a RMR of 2.6 ml∙kg–
1∙min–1 (mean value in our patients with low SMI), performing the same activity would be performing 
it at nearly seven times their RMR, and at a vigorous intensity (6.9 METs; vigorous PA defined as >6 
METs).2  
 
Further issues arising from individual differences in RMR relate to the use of predictive equations 
when prescribing exercise dose. For example, the ACSM metabolic equation for walking uses the 
estimated resting MET value.3 Using this established ACSM equation to estimate CRF in our patient 
cohort would mean that estimated V̇O2peak was 3.4% lower than actual peak V̇O2. This difference is 
10.6% lower in patients with low SMI. This observation implies that patients with a low SMI would 
undertake a relatively higher dose of exercise if they were prescribed exercise as a percentage of their 
estimated V̇O2peak. Prescribing a higher a dose of exercise makes standardising exercise-based 
research studies more challenging; negatively impacting intervention compliance, and may potentially 
lead to increased safety concerns in these patients. We propose that accounting for individualised 
differences in lean mass/SMI when prescribing exercise dose may be a relevant consideration when 
defining CRF or prescribing exercise intensity in patients with CHD (using the METs concept). Whilst 
direct measurement of RMR is not possible in most exercise-based CR programmes, skeletal muscle 
  
mass and RMR could be estimated with sufficient accuracy using bioelectrical impendence 
analysis/validated MET equations to identify patients with low RMR and/or SMI,10 which would allow 
exercise prescription to be  adjusted accordingly. 
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